MX2022000642A - Anticuerpos contra metalotioneina y su uso. - Google Patents
Anticuerpos contra metalotioneina y su uso.Info
- Publication number
- MX2022000642A MX2022000642A MX2022000642A MX2022000642A MX2022000642A MX 2022000642 A MX2022000642 A MX 2022000642A MX 2022000642 A MX2022000642 A MX 2022000642A MX 2022000642 A MX2022000642 A MX 2022000642A MX 2022000642 A MX2022000642 A MX 2022000642A
- Authority
- MX
- Mexico
- Prior art keywords
- metallothionein
- antibodies
- diabetes
- hepatitis
- fragments
- Prior art date
Links
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 title 1
- 102000003792 Metallothionein Human genes 0.000 title 1
- 108090000157 Metallothionein Proteins 0.000 title 1
- 201000009104 prediabetes syndrome Diseases 0.000 abstract 2
- 208000002705 Glucose Intolerance Diseases 0.000 abstract 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 208000001280 Prediabetic State Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 208000006454 hepatitis Diseases 0.000 abstract 1
- 231100000283 hepatitis Toxicity 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 230000000968 intestinal effect Effects 0.000 abstract 1
- 208000019423 liver disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
En la presente descripción se describen anticuerpos anti-metalotioneína aislados, o fragmentos de estos, y su uso en el tratamiento de inflamación intestinal, diabetes, prediabetes, intolerancia a la glucosa, hepatitis y/o enfermedad inflamatoria del hígado.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962874340P | 2019-07-15 | 2019-07-15 | |
| PCT/US2020/042064 WO2021011608A1 (en) | 2019-07-15 | 2020-07-15 | Metallothionein antibodies and their use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022000642A true MX2022000642A (es) | 2022-03-11 |
Family
ID=71895285
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022000642A MX2022000642A (es) | 2019-07-15 | 2020-07-15 | Anticuerpos contra metalotioneina y su uso. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220306731A1 (es) |
| EP (1) | EP3999531A1 (es) |
| JP (1) | JP2022542805A (es) |
| KR (1) | KR20220034811A (es) |
| CN (1) | CN114127105A (es) |
| AU (1) | AU2020315367A1 (es) |
| BR (1) | BR112022000705A2 (es) |
| CA (1) | CA3144014A1 (es) |
| IL (1) | IL289843A (es) |
| MX (1) | MX2022000642A (es) |
| WO (1) | WO2021011608A1 (es) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2729171B1 (en) * | 2011-07-08 | 2016-11-16 | Universiteit Gent | Use of antagonists targeting metallothionein to treat intestinal inflammation |
| SG11202006421RA (en) | 2018-01-17 | 2020-08-28 | Univ Connecticut | Methods for treating diabetes, hepatitis, and/or inflammatory liver disease |
-
2020
- 2020-07-15 AU AU2020315367A patent/AU2020315367A1/en active Pending
- 2020-07-15 WO PCT/US2020/042064 patent/WO2021011608A1/en unknown
- 2020-07-15 JP JP2022502219A patent/JP2022542805A/ja active Pending
- 2020-07-15 US US17/625,476 patent/US20220306731A1/en active Pending
- 2020-07-15 KR KR1020227003374A patent/KR20220034811A/ko unknown
- 2020-07-15 CA CA3144014A patent/CA3144014A1/en active Pending
- 2020-07-15 MX MX2022000642A patent/MX2022000642A/es unknown
- 2020-07-15 EP EP20750116.4A patent/EP3999531A1/en active Pending
- 2020-07-15 CN CN202080051788.2A patent/CN114127105A/zh active Pending
- 2020-07-15 BR BR112022000705A patent/BR112022000705A2/pt unknown
-
2022
- 2022-01-13 IL IL289843A patent/IL289843A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20220034811A (ko) | 2022-03-18 |
| EP3999531A1 (en) | 2022-05-25 |
| WO2021011608A1 (en) | 2021-01-21 |
| BR112022000705A2 (pt) | 2022-03-22 |
| CA3144014A1 (en) | 2021-01-21 |
| CN114127105A (zh) | 2022-03-01 |
| AU2020315367A1 (en) | 2022-02-03 |
| JP2022542805A (ja) | 2022-10-07 |
| IL289843A (en) | 2022-03-01 |
| US20220306731A1 (en) | 2022-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019004692A (es) | Anticuerpos 4-1bb anti-humano y usos de los mismos. | |
| CL2020003071A1 (es) | Proteínas de unión multiespecíficas y mejoras con estas | |
| MX2020010458A (es) | Conjugados de camptotecina-peptido. | |
| EA201792562A1 (ru) | Глюкагон и коагонисты гпп-1 | |
| MY194997A (en) | Anti-ccr7 antibody drug conjugates | |
| NO20074594L (no) | 39-Desmetoksy-derivater av rapamycin | |
| MXPA05012723A (es) | Tratamiento con anticuerpos anti-vgf. | |
| MX2021006681A (es) | Anticuerpos anti-claudina y usos de los mismos. | |
| MX357972B (es) | Materiales y metodos para el tratamiento o prevencion de enfermedades asociadas al her-3. | |
| MX2022003930A (es) | Conjugados de péptido de camptotecina. | |
| WO2018183182A8 (en) | Methods and compositions for reduction of immunogenicity | |
| MX2022005411A (es) | COMPUESTOS DE UNIÓN A IL-2RßYC. | |
| EA200801853A1 (ru) | Пептиды, эффективные в лечении опухолей и других заболеваний, требующих удаления или разрушения клеток | |
| BR112022002837A2 (pt) | Anticorpo anti-vd1 ou fragmento do mesmo, anticorpo multiespecífico isolado ou fragmento do mesmo, anticorpo humano e anticorpo multiespecífico isolado humano ou fragmento do mesmo | |
| DK1572087T3 (da) | Antistoffer med cancerantigen TMEFF2 og anvendelser deraf | |
| MX2021007235A (es) | Tubulisinas y conjugados de proteina-tubulisina. | |
| CO2022002622A2 (es) | Anticuerpos anti-cd73 y composiciones | |
| BR112022010179A2 (pt) | Anticorpos anti-vírus da febre amarela, e métodos de sua geração e uso | |
| LU92202I2 (fr) | Aflibercept | |
| MX2020006171A (es) | Terapia de combinacion con anticuerpos anti interleucina-8 (il-8) y anticuerpos anti receptor de muerte programada (pd-1) para tratar cancer. | |
| EA202091533A1 (ru) | Способы лечения диабета, гепатита и/или воспалительного заболевания печени | |
| MY194084A (en) | Interferon beta antibodies and uses thereof | |
| EP4186519A4 (en) | INTERFERON-BASED CANCER TREATING METHOD AND PHARMACEUTICAL COMPOSITION | |
| BR112018000909A2 (pt) | imunoconjugados de il22 | |
| WO2020180712A8 (en) | Anti-tnfr2 antibodies and uses thereof |